Benutzer: Gast  Login
Article; Journal Article
Kayser, Sabine; Schlenk, Richard F; Lebon, Delphine; Carre, Martin; Götze, Katharina S; Stölzel, Friedrich; Berceanu, Ana; Schäfer-Eckart, Kerstin; Peterlin, Pierre; Hicheri, Yosr; Rahme, Ramy; Raffoux, Emmanuel; Chermat, Fatiha; Krause, Stefan W; Aulitzky, Walter E; Rigaudeau, Sophie; Noppeney, Richard; Berthon, Celine; Görner, Martin; Jost, Edgar; Carassou, Philippe; Keller, Ulrich; Orvain, Corentin; Braun, Thorsten; Saillard, Colombe; Arar, Ali; Kunzmann, Volker; Wemeau, Mathieu; De Wit, Maik...    »
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
The aim of this study was to characterize a large series of 154 patients with acute promyelocytic leukemia (median age, 53 years; range, 18-90 years) and evaluate real-life outcome after up-front treatment with arsenic trioxide and all-trans retinoic acid. All patients were included in the prospective NAPOLEON registry (NCT02192619) between 2013 and 2019. The acute promyelocytic leukemia was de novo in 91% (n=140) and therapy-related in 9% (n=14); 13% (n=20) of the patients were older than 70 years. At diagnosis bleeding/hemorrhage was present in 38% and thrombosis in 3%. Complete remission was achieved in 152 patients (99%), whereas two patients (1%) experienced induction death within 18 days after starting therapy. With a median follow-up of 1.99 years (95% confidence interval: 1.61-2.30 years) 1-year and 2-year overall survival rates were 97% (95% confidence interval: 94-100%) and 95% (95% confidence interval: 91-99%), respectively. Age above 70 years was associated with a significantly shorter overall survival (P<0.001) compared to that of younger patients. So far no relapses have been observed. Six patients (4%) died in complete remission at a median of 0.95 years after diagnosis (range, 0.18-2.38 years). Our data confirm the efficiency and durability of arsenic trioxide and all-trans retinoic acid therapy in the primary management of adults with low-/intermediate-risk acute promyelocytic leukemia in the real-life setting, irrespective of age.
Band / Volume:
Heft / Issue:
Seitenangaben Beitrag:
Volltext / DOI:
TUM Einrichtung:
1605; 608; III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)